Evaluation of the time dependent variability of the anti-factor Xa activity of therapeutic nadroparin in critically ill patients: a pharmacokinetic study
Completed
- Conditions
- Farmacokinetiek van therapeutisch gedoseerd Nadroparinepharmacokinetics nadroparin
- Registration Number
- NL-OMON48502
- Lead Sponsor
- Martini Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
(1) Admitted to the Intensive Care with nadroparin in therapeutic dose (1-daily
or 2-daily)
(2) Age * 18 years
Exclusion Criteria
(1) Pregnancy
(2) Requiring hemodialysis (HD) or Continuous Veno-Venous Hemofiltration (CVVH)
(3) Treated with a DOAC, unfractionated heparin, another LMWH, a GP IIb / IIIa
receptor antagonist 96 hours to 0 hours before the first bloodsample is drawn
or during bloodsampling.
(4) Participation in another study
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>{[Cmax at tmax] minus [minimal measured anti-Xa between T3h to 5h] / [Cmax at<br /><br>tmax] } · 100%</p><br>
- Secondary Outcome Measures
Name Time Method <p>To evaluate the pharmacokinetics of therapeutic nadroparin in a general<br /><br>intensive care unit population by measuring anti-factor Xa levels.</p><br>